Advertisement


Judy C. Boughey, MD, on New Findings on the Impact of Breast Conservation Therapy on Local Recurrence

2022 San Antonio Breast Cancer Symposium

Advertisement

Judy C. Boughey, MD, of Mayo Clinic, talks about why breast-conserving therapy may be a treatment option for some patients with multiple breast lesions. For most patients who present with two or three sites of cancer in one breast, mastectomy is recommended. But results from the ACOSOG Z11102 (Alliance) suggest that for women with multiple ipsilateral breast cancer, breast-conserving surgery with adjuvant radiation therapy and lumpectomy site boosts may be beneficial (Abstract GS4-01).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Historically, women who have multiple ipsilateral breast cancer have usually been recommended to undergo a mastectomy. And this has been based on historical studies that have shown high rates of local recurrence in patients treated with breast conserving surgery followed by radiation when that patient has two or three or more foci of cancer within the breast. However, importantly more recent, his single institution retrospective studies have shown more acceptable local recurrence rates with breast conservation therapy in patients with multiple ipsilateral breast cancer. And so because of this, we designed the ACOSOG Z11102 clinical trial. We designed this as a prospective single arm phase two clinical trial, enrolling patients with two or three foci of biopsy proven breast cancer within one breast to be treated with breast conserving therapy. The protocol allowed lumpectomy to be performed via a single or multiple incisions and oncoplastic surgery was allowed. Nodal surgery was required and could be performed by either sentinel node surgery or [inaudible 00:01:11] lymph node dissection. And then the protocol required whole breast radiation with radiation boost to each of the prior lumpectomy sites. Patients were not allowed to have neoadjuvant therapy on this trial, but all patients with ER positive disease were recommended endocrine therapy and adjuvant systemic therapy was at the discretion of the treating medical oncologist. The patients were followed up every six months for a five-year follow up. The primary endpoint of this trial was to see the five-year estimated local recurrence rate where a clinically acceptable rate determined to be less than 8%. The primary endpoint of this study revealed that the five-year local recurrence rate was 3.1% and the confidence intervals remained below that 8% clinical threshold. So overall, this is a positive study showing that the local recurrence rate is clinically acceptable after breast conserving therapy, which includes lumpectomy followed by whole breast radiation for patients with two or three foci of disease in their breast. As we look at the study population, vast majority of patients had two foci of breast cancer with only seven patients having three foci of disease. And so as this is implemented into clinical practice, I anticipate that this will be most widely applicable to those patients that have two sites of breast cancer identified on their preoperative workup. This was also limited to patients 40 and older, and the vast majority of patients had clinically node negative disease and had ER positive HER2 negative disease. Now, the caveat to this is that the number of patients without a preoperative MRI was low with only 15 patients without a preoperative MRI. But we did notice a statistically significant difference in local recurrence with the absence of a use of preoperative MRI. And this was an unplanned secondary analysis, but I think it's judicious to consider preoperative MRI in patients who have two foci disease that where you are considering breast conserving surgery. Another key finding of this study was that those patients with ER positive disease that did not have adjuvant endocrine therapy had a higher local recurrence rate than those patients that did receive adjuvant endocrine therapy. And this is similar to what we see across all other treatments of breast cancer. And so this reiterates that adjuvant endocrine therapy is an important component of the treatment for patients with multiple ipsilateral breast cancer who are proceeding with breast conserving therapy. Overall, we think that this study is very exciting and we hope that this will open up breast conserving therapy as an option for more women who are diagnosed with newly diagnosed breast cancer. In particular, those women with two sites of disease where historically many teams may have recommended mastectomy, and now these teams in these patients may consider breast conserving therapy as an option for the patient's shared decision making.

Related Videos

Breast Cancer

Mafalda Oliveira, MD, PhD, on Camizestrant vs Fulvestrant in Advanced Breast Cancer: New Phase II Results

Mafalda Oliveira, MD, PhD, of Spain’s Vall d’Hebron University Hospital and Institute of Oncology, discusses findings from the SERENA-2 trial, which compared the next-generation selective estrogen receptor degrader camizestrant to fulvestrant in patients with hormone receptor–positive, HER2-negative breast cancer. Camizestrant, which can be taken as a daily pill (as opposed to fulvestrant, which must be given via injection), improved progression-free survival by up to 42% (Abstract GS3-02).

 

Breast Cancer

Sean Khozin, MD, MPH, on Randomized Trials vs Real-World Evidence in Patients With Advanced Cancer

Sean Khozin, MD, MPH, of the Massachusetts Institute of Technology, discusses the “external validity deficits” of randomized clinical trials, which still involve only about 5% of adults with cancer, who may differ in important ways from real-world populations. Dr. Khozin describes the reasons for low levels of participation and advocates for capturing the experience of patients not represented in traditional clinical trials, so real-world data can address these validity deficits.

Breast Cancer

Nicholas C. Turner, MD, PhD, on New Data on Capivasertib and Fulvestrant for Advanced Breast Cancer

Nicholas C. Turner, MD, PhD, of London’s Institute of Cancer Research and The Royal Marsden, discusses phase III results from the CAPItello-291 clinical trial, which showed that in patients with hormone receptor–positive, HER2-negative tumors resistant to aromatase inhibitors, adding the investigational AKT inhibitor capivasertib to fulvestrant doubled the median progression-free survival compared with placebo plus fulvestrant (Abstract GS3-04).

Breast Cancer

Ruth O’Regan, MD, on Evaluation of the Breast Cancer Index in Early-Stage Breast Cancer

Ruth O’Regan, MD, of the University of Rochester Medical Center, discusses the Breast Cancer Index (BCI), a genomic assay that can assess the risk of late distant recurrence (5–10 years after diagnosis) of hormone receptor–positive, early-stage breast cancer. Among premenopausal women with this disease who were enrolled in the SOFT trial, those with a high BCI score had an increased risk of distant recurrence. Those with a low BCI score benefited more from the addition of ovarian suppression therapy to endocrine therapy after 12 years of follow-up (Abstract GS1-06).

Breast Cancer

Ann H. Partridge, MD, MPH, on Interrupting Breast Cancer Treatment to Attempt Pregnancy

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the POSITIVE trial, which showed that a temporary interruption of endocrine therapy in women with hormone-responsive breast cancer in order to attempt pregnancy, does not affect short-term disease outcomes. The study found that 74% of women had at least one pregnancy, most (70%) within 2 years. Birth defects were low (2%) and were not clearly associated with treatment exposure. Dr. Partridge explains that these data stress the need to incorporate patient-centered reproductive health care in the treatment and follow-up of young women with breast cancer (Abstract GS4-09).

Advertisement

Advertisement




Advertisement